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ABSTRACT
Hepatitis B in At-Risk Groups in West Virginia: Three Studies to Guide Education, Testing, and
Vaccination Efforts
Stacy Tressler

Background and Objectives: For over a decade, West Virginia’s (WV) rate of acute hepatitis B
has been the highest in the United States (US). In 2017, WV’s rate was 11.7 per 100,000
population, almost 12 times higher than the national rate. The increase in acute hepatitis B cases
is largely due to substance misuse, including injection drug use (IDU). Hepatitis B is a vaccine
preventable disease yet many at-risk adults remain unvaccinated and susceptible to infection.
The objectives of our studies are to 1) describe yearly changes in acute hepatitis B incidence in
WV and assess county-level impact of the WV Pilot Project using geospatial methods 2) assess
hepatitis B vaccine dose completion by setting type in at-risk groups and 3) understand factors
associated with hepatitis B virus (HBV) exposure in an emerging at-risk group of people who
report using methamphetamine.
Methods: Study 1. County rates of acute hepatitis B and vaccine doses per 100,000 population
were visualized biannually from 2011 to 2018. Local indicators of spatial autocorrelation were
used to detect county-level clustering. Significant differences in the median rate of acute
hepatitis B pre and post intervention in counties receiving vaccine were evaluated using
Wilcoxon signed-rank test and bootstrapping estimates. A Bland-Altman graph visualized
significant differences in county-level rates of acute hepatitis B before and after the WV Pilot
Project compared to the statewide estimate. Study 2. Deidentified data were collected from local
health departments (LHDs) receiving hepatitis B vaccine through the WV Pilot Project and for
which participant forms were available. The odds of receiving all three or at least two doses of
hepatitis B vaccine were calculated using bivariate, multivariable, and mixed-effects regression
models. Study 3. National Health and Nutrition Examination Survey data were utilized to
examine factors associated with HBV exposure among participants who reported ever using
methamphetamine using bivariate and multivariable logistic regression.
Results: Study 1. Analyses identified significant geographic clustering of acute hepatitis B in
southern WV across all four time-periods. Nine of the 18 (50%) counties receiving vaccine had
significant declines in acute hepatitis B incidence compared to the statewide mean difference
estimate. Study 2. Ten LHDs had data available representing 1,201 participants. In multivariable
logistic regression, participants vaccinated at substance use treatment centers (aOR: 1.37; 95%
CI: 1.01-1.86) and LHD family planning clinics (aOR: 3.74; 95% CI: 1.98-7.06) were more
likely to receive the three-dose series compared to those vaccinated at LHD STD clinics. For the
secondary outcome, participants vaccinated through substance use treatment centers (aOR: 1.79;
95% CI: 1.31-2.44), correctional facilities (aOR: 3.34; 95% CI: 2.09-5.34), and LHD family
planning clinics (aOR: 3.97; 95% CI: 1.72-9.16) were significantly more likely to receive at least
two doses. Study 3. Overall, 847 participants representing approximately 11,048,115 people, met
the study inclusion criteria. In multivariable logistic regression, female sex (aOR 3.83, 95% CI
1.65 – 8.90), living below the poverty threshold (aOR 3.17, 95% CI 1.39 – 7.21), injection drug
use (IDU) (aOR 4.89, 95% CI 1.95 – 12.26), active hepatitis C (HCV) infection (aOR 3.39, 95%

CI 1.10 – 12.26), and identifying as men who have sex with men (aOR 28.21, 95% CI 5.19 –
153.38) were significantly associated with HBV exposure.
Conclusions: Despite the availability of a safe and effective hepatitis B vaccine, many
individuals remain at risk of infection. Hepatitis B virus transmission continues in WV due in
part to injection drug use and substance misuse. Ongoing efforts are needed to identify trends,
guide testing and vaccination programs, and evaluate the effectiveness of those programs.
Increased dissemination of hepatitis B vaccine through local health departments and existing
harm reduction services can reduce the incidence of acute hepatitis B in states such as WV,
which have been disproportionately affected by substance misuse.
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INTRODUCTION
Hepatitis B is a liver disease resulting from infection with hepatitis B virus (HBV); a small
partially double stranded DNA virus that infects humans [1]. The virus is spread through contact
with blood and body fluids, is highly infectious, and environmentally stable; remaining viable on
surfaces at room temperature for up to seven days [2]. HBV is estimated to be ten time more
infectious than the hepatitis C virus (HCV) and one hundred times more infectious than human
immunodeficiency virus (HIV) [3].
Infection with HBV results in an acute infection that may or may not be accompanied by signs
and symptoms. Symptoms include fatigue, loss of appetite, nausea, vomiting, right upper
quadrant pain, fever, headache, myalgia, dark urine, and jaundice [4, 5]. More than 85% of
children and 50% of adults are asymptomatic [4]. The incubation period ranges from 45 days to
160 days with an average of 90 days [6]. People acutely infected are able to transmit the virus
one to two months before and after the onset of symptoms. About 1% of people acutely infected
with HBV will develop fulminant hepatitis possibly resulting in death [7]. Acute infection can
progress to a life-long chronic infection with age being the greatest factor in progression to
chronicity [5, 8, 9]. Approximately, 90 to 95% of infants infected at birth will develop a chronic
infection while only 5 to 10% of adults will progress to the chronic carrier state [9, 10]. About
50% of people chronically infected are unaware of their infection and remain a source of ongoing transmission [11, 12].
Hepatitis B virus infects liver cells resulting in chronic inflammation. Complications of chronic
infection with HBV include cirrhosis, liver failure, hepatocellular carcinoma (HCC), and death
[6, 10]. It is estimated that chronic infection is responsible for 50% of all cases of HCC and 25%
of people with chronic infection will die prematurely from complications of the disease [11, 13].
There is no cure for hepatitis B, only treatment to slow the progression of disease.
Hepatitis B is a significant public health problem worldwide. Almost 90% of the world’s
population live in countries with either a high prevalence (greater than 8%) or intermediate
prevalence (between 2% and 7%) of hepatitis B [14, 15]. Those living in high prevalence areas
have a greater than 60% lifetime risk of acquiring hepatitis B while those living in an
intermediate areas have a lifetime risk between 20% and 60% [14]. In countries with high or
intermediate hepatitis B prevalence, most infections occur via vertical transmission during
1

childbirth or are acquired during childhood [16-18]. Estimates of the number of people
chronically infected with HBV are as high as 350 million. The World Health Organization
(WHO) estimates that globally approximately 3.5% of the world’s population (257 million
people) are living with chronic HBV infections and an estimated 887,000 people died in 2015 as
a result from disease complications [17, 19]. If current rates of hepatitis B remain unchanged, 20
million people are projected to die from HBV related disease complications by 2030 [16]. Due to
the global burden of all types of viral hepatitis, the WHO has developed a strategy to eliminate
viral hepatitis as a public health threat by 2030 [16].
In the US, the incidence of acute hepatitis B infections has decreased 75% over the past three
decades largely due to the implementation of universal vaccination of infants at birth in 1991 and
recommendation of catch-up vaccination of adolescents in 1997 [20-22]. Despite decreases in the
incidence of new infections, an estimated 800,000 to 2.2 million people are living with chronic
infections [5, 23]. Estimates using National Health and Nutrition Survey (NHANES) data
indicate the prevalence of chronic hepatitis B in the United States has remained around 0.3%
since 1999 due in part to immigration of foreign-born persons from endemic countries [24].
Approximately, 70% of people chronically infected persons in the United States are foreign-born
with nearly 50% of chronic infections occurring in non-Hispanic Asians [5, 23].
Since 2006, the rate of acute HBV infections in the U.S. has remained stable at around 1 case per
100,000 people [25, 26]. Major risk factors for acute HBV infection in the U.S. include injection
drug use and multiple sexual partners [26]. Over the past decade, substance misuse has resulted
in a resurgence in cases of acute hepatitis B in certain high-risk groups including people who
inject drugs (PWID) [27, 28]. Nationwide, in 2015 the highest incidence of acute hepatitis B
occurred among persons 30 to 39 years of age with 30% of newly infected people reporting IDU
as a risk factor [28]. Most notably, there was a substantial increase in acute hepatitis B cases in
parts of central Appalachia including Kentucky, Tennessee, and West Virginia (WV). From
2009-2013, there was a 114% increase in the number of newly reported acute infections in these
three states [25]. The majority of cases occurred among non-Hispanic whites, 30 to 39 years of
age with 75% reporting IDU as a risk factor [25].
PWID are at an increased risk of becoming infected with HBV through sharing of equipment to
inject drugs and sexual contact [29]. Estimates of the non-institutionalized U.S. population
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indicate that around 19.7% to 27.3% of PWID have serological lab markers consistent with past
or present infection compared to just 4.6% of the general population [30, 31]. Adults with
compromised immune systems are more likely to develop chronic infections and PWID may
have a higher risk of developing chronic infection due to altered immune function and coinfections with HCV and HIV [11, 32, 33]. Co-infections coupled with chronic drug use can
result in increased morbidity and mortality as well as accelerated progression of liver disease
[29]. Hepatitis B vaccination is recommended for PWID but despite this recommendation
vaccination rates among PWID remains low [34]. Only an estimated 15% to 20% of PWID have
lab markers consistent with vaccine-induced immunity compared to 23% to 30% of U.S. adults
[31, 35, 36]. From 2003 to 2014, seroprevalence of vaccine-induced immunity increased in the
general U.S. population but not in PWID, men who have sex with men (MSM), and people with
chronic hepatitis C [35]. Low vaccination rates coupled with high-risk behaviors and reduced
immune response to the vaccine means that many at-risk individuals remain vulnerable to
acquiring HBV [32, 33].
Rural areas have been disproportionately affected by the opioid crisis and disease transmission
associated with IDU. An outbreak of HIV associated with IDU in rural Scott County prompted a
nationwide county-level vulnerability of assessment to identify counties at high-risk for a similar
outbreak [37, 38]. The assessment identified 220 counties in 26 states at risk for HIV and HCV
transmission among PWID [38]. Twenty-eight of the 220 counties identified by the assessment
were in WV, with two WV counties ranking in the top 10 (McDowell #2 and Mingo #7) [38].
Existing high rates of acute hepatitis B in WV coupled with vulnerability to outbreaks of
infections associated with IDU, indicates the potential for ongoing transmission of HBV along
with the risk of co-infections with HIV and HCV.
Despite decreasing trends nationwide, the rate of new HBV infections in WV has steadily
increased since 2002 (Figure 1) [39]. In 2016, WV’s rate of acute hepatitis B was 14.7 per
100,000, almost 15 times the national average [40]. Since 2006, WV has ranked first in the
nation with the highest rate of acute hepatitis B and either first or second for acute hepatitis C
[26]. West Virginia rates of acute hepatitis B and hepatitis C have mirrored overdose mortality
rates (Figure 2). From 2012-2016, the rate of acute hepatitis B cases was highest among males,
persons 30 to 39, and cases were concentrated in the southern region of the state [41]. In 2016,
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the most common risk factors reported in WV among people with acute hepatitis B was IDU or
street drug use [42]. Given ongoing issues of substance misuse across WV, transmission of
hepatitis B will continue among at-risk groups unless additional efforts are made to identify and
prevent HBV infections in those with the highest risk of exposure.
Along with opioid use, nationwide use of methamphetamine is rising due to an increase in the
availability of cheaper, more potent methamphetamine flooding the US from Mexico [43, 44].
From 2010 to 2018, the number of methamphetamine seizures at the US border increased
dramatically from 8,900 pounds to 82,000 respectively [44]. Methamphetamine use in the US
peaked around 2005 but has reemerged as a threat in recent years [43, 45]. From 2011 to 2016,
the number of overdose deaths involving methamphetamine more than tripled and accounted for
11% of overdose deaths in 2016. Additionally, a recent study found methamphetamine use
almost doubled from 18.8% in 2011 to 34.2% in 2017 among people using opioids who sought
treatment in the US [46].
Hepatitis B in people who use methamphetamine is not well described in the literature but its
use, either through parenteral or non-parenteral routes, increases the risk for acquiring sexually
transmitted infections including hepatitis B [47]. Recently, methamphetamine has been
implicated in an increase in acute hepatitis B cases, as well as an increase in hepatitis C, HIV,
and syphilis in the US and parts of Canada [48, 49]. In line with nationwide trends, overdose
trends in WV suggest methamphetamine use is increasing across the state. In WV, the number of
overdose deaths involving methamphetamine increased from 49 in 2015 to 323 in 2018 with
36% of all overdose deaths in 2018 involving methamphetamine (Figure 3) [50, 51]. The
increase in methamphetamine use and co-use with opioids represents a public health threat
requiring a refocusing of response efforts in WV.
Hepatitis B remains a real and ongoing threat to a number of at-risk groups, including people
who use drugs and those engaging in high-risk sexual behaviors. It is recommended that at-risk
people without serological evidence of HBV infection or immunity be vaccinated against HBV
[27]. As substance misuse continues in WV, it is important to understand factors associated with
HBV exposure among at-risk populations to help guide education, testing, and vaccination
efforts.
Purpose Statement:
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The objectives of our studies are to describe yearly changes in acute hepatitis B incidence and
assess county-level impact of the WV Pilot Project using geospatial methods, assess hepatitis B
vaccine dose completion by setting type in at-risk groups, and understand factors associated with
HBV exposure in an emerging at-risk group of people using methamphetamine. Study findings
will contribute to knowledge about changes in the geographic distribution of hepatitis B in WV
to help inform surveillance activities and placement of harm reduction services. Additionally,
results will improve future vaccination programs and efforts among individuals at risk of HBV
infection.
Specific Aim 1. Use geospatial methods to examine changes in the distribution of acute hepatitis
B in West Virginia in relation to counties participating in the WV Pilot Project.
Purpose of Study 1. Despite having the highest rate of acute hepatitis B for over a decade,
spatial trends in WV have not been examined over time. Visualizing trends and conducting
cluster analyses can inform placement of harm reduction services, identify areas in need of
enhanced surveillance, guide future vaccination efforts, and help evaluate the impact of
interventions. Our study will incorporate a variety of geospatial methods to assess county-level
distribution of acute hepatitis B rates before, during, and after the WV Pilot Project, identify
county-level hotspots, and identify areas in need of additional hepatitis B prevention efforts.
Specific Aim 2. Determine which setting type is associated with higher odds of completing all
three or at least two doses of hepatitis B vaccine among at-risk individuals vaccinated through
local health departments as part of a vaccine pilot project.
Purpose of Study 2. Completion of the three-dose hepatitis B vaccination among at-risk adults
remains a challenge. Despite WV’s participation in two federally funded hepatitis B vaccine
initiatives (Adult Hepatitis B Vaccination Initiative, 2007–2009 and HepB Pilot Program, 20132015), the effectiveness of such initiatives has not been evaluated. Our study will examine
factors associated with completion of the three-dose hepatitis B vaccine in local health
departments. Findings from this study will be valuable in informing future vaccination efforts
among at-risk populations. There is a gap in the literature regarding strategies to increase
hepatitis B vaccination in at-risk groups in rural areas. Given current drug misuse in Appalachia,
this is an especially important and timely topic for both hepatitis A and B.
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Specific Aim 3. Identify factors associated with HBV exposure among people who report using
methamphetamine.
Purpose of Study 3. People who use methamphetamine are at an increased risk of exposure
from high-risk sexual behaviors and equipment used to administer the drug. Documented
increases in reported methamphetamine use among people diagnosed with primary and
secondary syphilis indicates there is an association between methamphetamine use and risky
sexual behaviors [49]. Our study will examine factors associated with methamphetamine use and
HBV exposure to identify groups potentially at an increased risk of infection.
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Figure 1. Acute Hepatitis B Incidence Rate per 100,000 Population in West Virginia & United States, 1996 - 2017
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Acute Hepatitis B & C Rate per 100,000 Population
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100,000 Population — West Virginia, 2007-2017
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Figure 3. Number of Fatal Drug Overdose Deaths and Select Substances — West Virginia, 2001-2018
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CHAPTER ONE
Impact of a Vaccine Intervention on County-Level Rates of Acute Hepatitis B in West Virginia,
2011-2018

ABSTRACT
The rate of acute hepatitis B in West Virginia (WV) has been increasing since 2006. To reduce
new infections, WV implemented a vaccine intervention (WV Pilot Project), which provided
over 10,000 doses of hepatitis B vaccine to at-risk adults in 18 counties. The objectives of this
study were to describe yearly changes in acute hepatitis B incidence and assess county-level
impact of the WV Pilot Project using geospatial methods. County rates of acute hepatitis B and
vaccine doses per 100,000 population were visualized biannually from 2011 to 2018. Local
indicators of spatial autocorrelation were used to detect county-level clustering. Significant
differences in the median rate of acute hepatitis B pre and post intervention in counties receiving
vaccine were evaluated using Wilcoxon signed-rank test and bootstrapping. A Bland-Altman
graph visualized significant differences in county-level rates of acute hepatitis B before and after
the WV Pilot Project compared to the statewide estimate. Analyses identified significant
geographic clustering of acute hepatitis B in southern WV across all four time-periods. Nine of
the 18 (50%) counties receiving vaccine had significant declines in acute hepatitis B incidence
compared to the statewide mean difference estimate. Findings suggest that increased
dissemination of hepatitis B vaccine through local health departments and existing harm
reduction services can reduce the incidence of acute hepatitis B in states such as WV, which
have been disproportionately affected by substance misuse.
Keywords: Hepatitis B; Hepatitis B vaccine; Cluster analysis; Vaccine intervention
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INTRODUCTION
Hepatitis B is a liver disease resulting from infection with the hepatitis B virus (HBV).
Complications of infection include fulminant hepatitis, cirrhosis, liver failure, hepatocellular
carcinoma, and death [1]. The virus is spread through contact with blood and body fluids, is
highly infectious, and environmentally stable on hard surfaces for more than seven days [2]. In
the United States, major risk factors for infection include sexual exposure and injection drug use
[3, 4]. People who inject drugs (PWID) are at an increased risk of acquiring hepatitis B
infections through sharing of equipment to inject drugs and sexual contact [4, 5]. Estimates of
the noninstitutionalized civilian United States population indicate that approximately 20 to 27%
of PWID have lab markers consistent with past or present HBV infection compared to just 4.6%
in the general population [6, 7].
Over the past three decades, the incidence of new HBV infections in the United States has
declined 75% due to universal vaccination of infants at birth, catchup vaccinations of
adolescents, and human immunodeficiency virus (HIV) prevention efforts in men who have sex
with men and PWID [8-10]. However, the increase in substance misuse and injection drug use
over the past decade has resulted in a resurgence of acute cases of hepatitis B among at-risk
groups especially in parts of Appalachia [4, 11, 12]. Despite the decreasing trend nationwide, the
rate of acute HBV infections in West Virginia (WV) has steadily increased since 2006. In 2016,
WV’s rate of acute HBV infections was 14.7 per 100,000 population, almost 15 times the
national average of 1 per 100,000 population [10, 13]. Appalachian states, in particular
Kentucky, Tennessee, and West Virginia, have been disproportionately affected by opioid
misuse [12]. From 2009 to 2013, the three states reported a 114% increase in the number of
reported acute hepatitis B cases [12]. The majority of these cases occurred in non-Hispanic
whites, ages 30 to 39, with 75% of all cases reporting injection drug use as a risk factor [12].
From 2012 to 2016, injection and non-injection drug use were the two most commonly reported
risk factors among people with acute hepatitis B in WV [13, 14]
The CDC’s Advisory Committee on Immunization Practices (ACIP) currently recommends
adults with risk factors, including recent or current injection drug use, receive hepatitis B
vaccination as they may have reduced immunity or not completed all three doses of vaccine [4].
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In January 2013, the West Virginia Bureau for Public Health, Office of Epidemiology and
Prevention Services (WV OEPS) initiated the West Virginia Hepatitis B Vaccination Pilot
Program (WV Pilot Project), part of a larger CDC funded HepB Vaccine Pilot Program
implemented in 14 local and state health departments nationwide [15]. The goal of the two-year
project in WV was to decrease the number of new HBV infections by providing over 10,000
doses of vaccine to at-risk adults in 18 counties with higher rates of acute hepatitis B [12, 16].
Vaccine was administered to adults considered at-risk for HBV infection at sites where universal
HBV vaccination is recommended including HIV clinics, local health department (LHD) STD
clinics, and LHD community partnerships with local substance use treatment centers and
correctional facilities [15-17].
The objectives of this study were to describe yearly changes in county-level acute hepatitis B
incidence and assess the impact of the WV Pilot Project using geospatial methods.
METHODS
For this retrospective study, 2011-2018 acute hepatitis B data and the number of HBV vaccine
doses provided to WV Pilot Project counties were obtained from WV OEPS. Acute hepatitis B
case counts by county are the result of cases identified through the Nationally Notifiable Disease
Surveillance System and were limited to those meeting the CDC’s confirmed acute hepatitis B
case definition; defined as “a case that meets the clinical case definition, is laboratory confirmed,
and is not known to have chronic hepatitis B” [18]. Case data were incorporated into two-year
estimated rates based on the years of vaccine distribution to counties participating in the WV
Pilot Project; prior to vaccine distribution (2011-2012), during vaccine distribution (2013-2014
and 2015 -2016), and following vaccine distribution (2017-2018). Geospatial methods, including
mapping and cluster analyses, were used to examine changes in the distribution of acute hepatitis
B in WV in relation to vaccination efforts. County rates were estimated in ArcMap 10.5.1 (ESRI
Redlands, CA) using mid-year U.S. Census population estimates and joined to a WV counties
shape file [19, 20]. Rate per 100,000 population of acute hepatitis B for each period were
visualized using a quartile classification to highlight spread of the data, with darker colors
indicating higher rates of acute hepatitis B. Vaccine doses per 100,000 population were
calculated by dividing the total number of doses received by each county by their total
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population and multiplying by 100,000. The resulting rates were visualized using graduated
symbols, with larger symbols indicating greater distribution of vaccine doses.
Local Empirical Bayes Moran’s I and local indicators of spatial autocorrelation (LISA) maps
were included to identify county-level acute hepatitis B clusters during each time-period using
GeoDa 1.12 (GeoDa Center, AZ). To perform the cluster analyses, two-year case counts were set
as the event variable, and midyear county-level census estimates were set as the base variable. A
queen’s contiguity weight was specified to maximize neighbors involved and cluster analyses
results were permuted 99999 times to increase robustness of analyses and identify statistically
significant areas of high county-level acute hepatitis B rates [21]. Statistical significance was
assessed at the 0.05 alpha level. The null hypothesis for the local cluster analysis was a random
pattern of county-level rates of acute hepatitis B with no local spatial association [22].
A Wilcoxon signed-rank test was used to detect a significant change in the median rate of acute
hepatitis B per 100,000 population in WV Pilot Project counties before (2011-2014) and after
(2015-2018) the intervention. Due to the small sample size of counties included in the analysis,
bootstrapping was used to estimate the median rate change and 95% confidence interval, and to
validate estimates from the Wilcoxon signed-rank test. A Bland-Altman graph, which plots the
difference between two paired measurements against its mean, was used to visualize significant
differences in county-level rates of acute hepatitis B per 100,000 population in all WV counties
before and after the WV Pilot Project [23]. To assess statistical significance at the 0.05 alpha
level, the statewide mean difference and corresponding 95% confidence interval (CI) were
plotted. Counties with differences in rates of acute hepatitis B outside the upper or lower bounds
of the 95% CI were considered significant.
RESULTS
County-level rates of acute hepatitis B per 100,000 population and the rate of vaccine doses per
100,000 are displayed in Figure 1.1. Overall, rates of acute hepatitis B were highest in southern
WV across the four time-periods. Zero case counts were present in 21 of 55 (38%) WV counties
in 2012-2013, decreasing to 10 of 55 (18%) by 2017-2018. The highest rates of acute hepatitis B
were observed in the southern counties, while the lowest rates were observed in northern
counties. Over the four time-periods, progressive increases in rates of acute hepatitis B were
observed in southern adjacent counties. Vaccine doses per 100,000 population ranged from 54.1
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to 4486.4, and were limited to 18 counties based upon population size and rates of acute hepatitis
B. The rate of vaccine doses per 100,000 indicates the magnitude of vaccine doses distributed in
relation to the county population with higher rates indicating a larger proportion of the
population potentially receiving vaccine.
County-level clustering in rates of acute hepatitis B in relation to vaccine doses per 100,000
population are displayed in Figure 1.2. Analysis of county-level clustering takes into account
rates in adjacent counties and identifies definite hotspots and coldspots or groups of counties
(cluster) with high or low rates of acute hepatitis B. While counties in clusters changed
somewhat over each time period, in general, hotspots (high-high clusters) indicating statistically
significant clustering of high county-level rates of acute hepatitis B, were detected in southern
WV during all time-periods (n=7 in 2011-2012, n=9 in 2013-2014, n=9 in 2015-2016, and n=8 in
2017-2018). Over the four time-periods, the high-high clusters increased to include adjacent
counties to the north and west, indicating progressive expansion into counties neighboring the
initial multi-county hotspot. Of the nine counties identified in the 2013-2014 hotspot, seven
(78%) received vaccine doses. Cold spots (low-low clusters) indicating statistically significant
clustering of low county-level rates of acute hepatitis B, were detected in northern and eastern
WV counties during all time-periods (n=10 in 2011-2012, n=9 in 2013-2014, n=10 in 20152016, and n=9 in 2017-2018).
The median hepatitis B rate difference before and after the WV Pilot Project (calculated using
the Wilcoxon signed-rank test and bootstrapping) for participating counties was an increase of
1.21 per 100,000 population (95% CI, -13.29, 21.93) following the intervention, however the
increase was not significant (p-value = 0.90). Due to the small sample size of WV Pilot Project
counties included in the analysis (n=18), bootstrapping was used to estimate the median rate
difference along with a 95% CI. This resulted in a median rate decrease of -4.16 of acute
hepatitis B cases per 100,000 population (95% CI, -33.07, 19.36) following the intervention. The
Bland-Altman mean difference analysis found the statewide mean difference before and after
the intervention was an increase of 10.80 cases per 100,000 population (95% CI, 0.80, 20.79).
County-level differences in rates of acute hepatitis B before and after the WV Pilot Project and
the statewide mean difference and 95% CI are displayed in Figure 1.3. Twelve of the 18 WV
Pilot Project counties (67%) had a rate difference lower than the statewide estimate indicating a
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reduction in the rate of acute hepatitis B following vaccine distribution compared to the
statewide mean difference. Of these, nine (50%) had statistically significant declines as indicated
by a rate difference below the lower bound of the statewide 95% CI. However, four (22%) of the
18 WV Pilot Project counties had statistically significant increases in rates of acute hepatitis B
following the intervention compared to the statewide mean difference. Of the 37 non-Pilot
Project counties, 8 (22%) experienced a statistically significant decrease and 11 (30%) a
statistically significant increase as indicated by values below and above the 95% CI respectively.
DISCUSSION
In this study, we found the incidence rate of acute hepatitis B increased steadily across WV with
rates peaking in 2015-2016 and then slightly declining in 2017-2018. One of the most notable
findings of this study was the shift in counties identified as hotspots through cluster analyses
across the four time-periods. This shift suggests counties at risk for HBV transmission are
changing and additional efforts are needed in emerging hotspots. Two counties identified as
hotspots in all four time-periods did not receive vaccine through the WV Pilot Project
demonstrating a missed opportunity to vaccinate at-risk individuals. All counties identified as a
hotspot in the 2017-2018 cluster analysis may benefit from enhanced hepatitis B surveillance and
increased efforts to prevent new HBV infections.
While the median difference calculated using both the Wilcoxon signed-rank test and
bootstrapping estimates found non-statistically significant changes in the median rate of acute
hepatitis B in Pilot Project counties, the median difference estimate obtained via bootstrapping
indicates a decrease of 4.16 cases per 100,000 population (95% CI, -33.07, 19.36) after WV Pilot
Project implementation. Due to the small sample size of counties included in the analysis, the
bootstrapping estimate most likely provides a better approximation compared to the estimate
obtained from the Wilcoxon signed-rank test.
Another notable finding was the significant decrease in the rate difference before and after the
WV Pilot Project (as indicated by values below the statewide mean difference 95% CI) in nine
participating counties – Berkeley, Hancock, Harrison, Jefferson, Mason, McDowell, Mercer,
Mingo, and Wyoming. While eight of the 37 (22%) non-Pilot Project counties experienced a
similar decrease, a significant decrease was observed in 50% of WV Pilot Project counties.
These findings indicate that the WV Pilot Project may have reduced the number of new HBV
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infections in at-risk adults especially in the southern part of WV where the greatest acute
hepatitis B rate differences were observed. In total, 12 of the 18 WV Pilot Project counties had
acute hepatitis B rate differences below the WV mean difference and while not all of the results
were statistically significant, these findings point to the effectiveness of the WV Pilot Project in
reducing or stabilizing rates in these counties.
From 2013 to 2015, the WV Pilot Project administered over 10,000 doses of HBV vaccine to
adults considered at risk for HBV infection in 18 counties. At-risk adults were reached through
local health department STD clinics, correctional facilities, substance use treatment centers, and
HIV care facilities [15, 16]. Completion of the three-dose series was cited as a challenge
throughout the project [16]. In WV, of those who initiated the vaccine series, 59% received the
second dose, and 32% completed the three-dose series [16]. Although some protection is
conferred through receipt of one or two doses of hepatitis B vaccine, people who use drugs may
have an altered immune response and therefore less likely to be protected after receiving just one
or two doses [24]. Failure to complete the series, coupled with lower immune response may have
resulted in less at-risk individuals protected against HBV infection, thus reducing the impact of
the WV Pilot Project.
Strength and Limitations
Strengths of this study include the use of geospatial modeling, including cluster analyses, to
examine trends in acute hepatitis B over eight years in WV. Hotspots identified in the cluster
analyses indicate a statistically significant high county rate of acute hepatitis B in relation to the
surrounding counties representing a non-random pattern. Another strength is the use of
bootstrapping, which provides a better approximation of the median pre and post intervention
due to the small sample size of counties included in the estimation. Finally, the use of BlandAltman analysis to calculate and plot the difference in rates of acute hepatitis B before and after
the WV Pilot Project for comparison with the statewide mean difference and 95% CI, provides a
method to assess if the rate differences for individual counties were statistically significant.
Potential limitations of this study include a lack of county-specific data regarding the number of
participants who completed vaccination through the WV Pilot Project. However, vaccine doses
per 100,000 population in each county is an indication of the volume of vaccine distributed in
relation to the total population for that county. It is also unknown if people who initiated or
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completed the series developed immunity as post-serological testing was either not done or data
were not available. Previous studies have shown that immune response to hepatitis B vaccine is
lower in people with altered immune function including PWID, so not everyone vaccinated may
have developed immunity [24]. Additionally, the 2018 acute hepatitis B case counts from WV
OEPS used in all calculations were provisional and thus subject to change. Forty-four of the 55
WV counties have populations under 55,000 making the rates easily influenced by small case
counts. Combined time-periods were used in order to stabilize rates, but small counties were still
subject to large rates based on few cases of acute hepatitis B. Finally, many factors may have
resulted in either an increase or decrease in the incidence rates of acute hepatitis B infections
between the time-periods therefore making it difficult to determine the overall impact the WV
Pilot Project on incidence rates. The first WV harm reduction program with syringe exchange
opened in 2015 after the WV Pilot Project, and in 2017 there were 12 such programs [25].
Overall efforts to reduce the effects of substance misuse in WV may have reduced the number of
new acute hepatitis B infections. However, to our knowledge there have been no new statewide
hepatitis B vaccine initiatives since the WV Pilot Project.
CONCLUSION
Hepatitis B is a vaccine preventable disease, yet many at-risk adults remain unvaccinated and
susceptible to infection. Ongoing harm reductions efforts, including syringe exchange programs,
STD clinics, and LHD partnerships with community programs serving at-risk adults, should
incorporate hepatitis B testing and vaccination to reduce the number of new HBV infections.
Geographic information systems can guide surveillance efforts, placement of prevention
services, and direct future interventions by identifying trends and changes in new HBV
infections in WV.
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Figure 1.1 West Virginia county-level rates of acute hepatitis B from 2011 through 2018 and
vaccine doses per 100,000 population. Darker colors and larger circles indicate a higher rate of
acute hepatitis B and vaccine doses per 100,000 population respectively.

*The WV Pilot Project concluded in 2015
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Figure 1.2 West Virginia acute hepatitis B cluster analyses and vaccine doses per 100,000
population. High-high counties, depicted in black, are hotspots or a group of counties with high
rates of acute hepatitis B. Low-low counties, depicted in dark grey, are coldspots or a group of
counties with low rates of acute hepatitis B. High-low and low-high counties are spatial outliers
indicating a county with a high rate surrounded by counties with low rates or a county with a low
rate surrounded by counties with high rates of acute hepatitis B.

*The WV Pilot Project concluded in 2015
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Figure 1.3 Bland-Altman graph depicting the difference in acute hepatitis B rates per 100,000 population in WV Pilot Project and nonPilot Project counties compared to the mean difference for all of West Virginia before and after WV Pilot Project implementation.
Values above or below the 95% CI have statistically significant differences greater than or less than the mean difference for West
Virginia.
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CHAPTER TWO
Variations in Hepatitis B Vaccine Series Completion by Setting among
At-Risk Adults in West Virginia
ABSTRACT
Introduction: West Virginia (WV) leads the nation with the highest rate of acute hepatitis B.
From 2013 to 2015, the West Virginia Hepatitis B Vaccination Pilot Project (WV Pilot Project)
distributed over 10,000 doses of hepatitis B vaccine through local health department (LHD)
clinics and through LHD outreach to correctional facilities and substance use treatment centers to
at-risk adults. The objectives of this study were to determine which setting type was associated
with the greatest likelihood of receiving all three or at least two doses of hepatitis B vaccine.
Methods: Data for this retrospective cohort study were accessed, extracted, and analyzed in 2019
from WV Pilot Project participant forms initially completed from 2013 to 2015. The odds of
receiving all three or at least two doses were calculated using bivariate, multivariable, and
mixed-effects regression models.
Results: Data were available for 1,201 participants. In multivariable logistic regression,
participants vaccinated at substance use treatment centers (aOR: 1.37; 95% CI: 1.01-1.86) and
LHD family planning clinics (aOR: 3.74; 95% CI: 1.98-7.06) were more likely to receive the
three-dose series compared to those vaccinated at LHD STD clinics. For the secondary outcome,
participants vaccinated through substance use treatment centers (aOR: 1.79; 95% CI: 1.31-2.44),
correctional facilities (aOR: 3.34; 95% CI: 2.09-5.34), and LHD family planning clinics (aOR:
3.97; 95% CI: 1.72-9.16) were more likely to receive at least two doses.
Conclusion: Hepatitis B vaccination delivered at LHD family planning clinics, substance use
treatment centers, or correctional facilities may increase vaccine dose completion in WV.
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INTRODUCTION
West Virginia (WV) has been disproportionately affected by the opioid crisis resulting in
increased rates of acute hepatitis B [1-3]. For over a decade, WV’s rate of acute hepatitis B has
been the highest in the United States (U.S.) [1, 2]. In 2017, WV’s rate was 11.7 per 100,000,
almost 12 times higher than the national rate [1, 2]. This increase in acute hepatitis B virus
(HBV) infections is largely due to substance misuse, including injection drug use (IDU) [2, 3].
From 2012 to 2015, the Centers for Disease Control and Prevention (CDC) funded a vaccine
pilot program in 14 state and local health departments, including WV, to reduce the number of
new HBV infections in at-risk adults [4]. Adults were vaccinated in settings where universal
vaccination is recommended, and in specific settings where those with risk factors are typically
seen or who were living in communities with an increased incidence of acute hepatitis B [4, 5].
As part of the national pilot program, the West Virginia Hepatitis B Vaccination Pilot Program
(WV Pilot Project) distributed over 10,000 doses of HBV vaccine to the 18 counties with higher
rates of acute HBV [6]. Eighteen WV local health departments (LHDs) vaccinated at-risk adults
in their own STD, family planning, vaccine, and other clinics as well as through expanded
outreach to correctional facilities and substance use treatment centers through vaccine delivery
partnerships.
The objectives of this study were to determine which setting type was associated with the
greatest likelihood of receiving all three doses (primary objective) or at least two doses
(secondary objective) of the three-dose HBV vaccine series among WV Pilot Project participants
vaccinated through WV LHDs. Receipt of at least two doses of vaccine was chosen as the
secondary objective for two reasons. First, some protective antibody response is conferred from
receipt of just two doses of the standard 3-dose series, with approximately 75% of healthy adults
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achieving anti-HBs ≥ 10 mIU/mL after receiving two doses [5, 7, 8]. Second, in 2017, the FDA
approved a new two-dose, HBV vaccine called Heplisav-B that can be completed in just four
weeks compared to the minimum of 16 weeks needed to complete the traditional 3-dose series
[9, 10]. Therefore, understanding which sites were associated with completion of at least two
doses of HBV vaccine has implications for future vaccination efforts using either the traditional
3-dose series or the new 2-dose Heplisav-B vaccine.
METHODS
Deidentified data for this retrospective cohort study were accessed in 2019 from LHDs that
participated in the WV Pilot Project and extracted from available participant forms previously
completed from January 2013 through September 2015. This study was approved by the West
Virginia University Institutional Review Board.
Local health departments participating in the WV Pilot Project were contacted and invited to
participate in the study. Participants were eligible for inclusion in the study if they received at
least one dose of vaccine through the WV Pilot Project through a LHD; had not previously
started the HBV vaccine series elsewhere; were negative for all HBV lab markers if tested; were
not vaccinated at multiple settings; and had available data for both the main exposure variables
and vaccine dosage administration. A flow chart detailing inclusion criteria for the final sample
selection can be found in Figure 2.1. The three participating clinics serving persons with HIV
were not included in this study.
Outcome variables
The outcome for the primary objective, completion of the three-dose HBV vaccine series, was
defined as receiving all three doses at the appropriate dosing interval with at least four weeks
29

between doses one and two, at least eight weeks between doses two and three, and a minimum of
at least 16 weeks between doses one and three [11, 12]. Non-completion for the primary outcome
was defined as receiving one or two doses. The outcome for the secondary objective was defined
as receiving two doses of the three-dose HBV vaccine series; non-completion was defined as
receiving only one dose.
Exposure variables
The primary exposure variable, setting type, was restricted to the setting options available to
LHDs on the participant form. These included STD and other clinics located at LHDs, and LHD
outreach to correctional facilities and substance use treatment centers. Local health department
‘other clinics’ included participants vaccinated at any on-site LHD clinic other than the STD
clinic. A separate ‘LHD family planning’ category was derived from the ‘other clinics’ category
due to the number of participants who were vaccinated at this setting. Participants vaccinated
through ‘other clinics,’ including family planning, were required to have a risk factor. However,
people could state they did not wish to answer the risk factor information but would still like to
be vaccinated against hepatitis B. Due to differences among LHDs in coding for correctional
facilities and substance use centers, the two categories were standardized according to the
following criteria: settings that included regional jails, drug courts, and day report centers were
coded as ‘correctional facility’, and inpatient and outpatient drug treatment facilities, methadone
and buprenorphine clinics were coded as ‘substance use treatment center.’ Additional exposure
variables included sex, age, and race. Age was categorized as 18-29, 30-39, 40-49, and 50+ years
old. Race was categorized as ‘African American’ or ‘white/other/missing’ due to the majority of
participants identifying as ‘white.’
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Statistical analysis
Analyses were completed in 2019. SAS version 9.4 was used for all analyses with α set to 0.05.
Missing data were treated with pairwise deletion. Frequencies and percentages were calculated
for all exposure variables and both the primary and secondary outcomes. A Chi-squared test was
used to assess for significant relationships between the exposure variables and the outcomes.
Unadjusted odds ratios (uOR) with accompanying 95% Confidence Intervals (CI) were
calculated using bivariate logistic regressions with logit link and standard selection.
Multivariable logistic regressions were used to calculate the adjusted odds ratios (aOR) with
accompanying 95% CIs for the main exposure variable and primary and secondary outcomes
controlling for sex, age, and race. Mixed-effects generalized linear regression models
(GLIMMIX) were used to account for the random effects of participants nested within LHDs.
Exposure variables from the bivariate and multivariable models were included in the GLIMMIX
models.
In this study, ORs are reported in lieu of risk ratios (RR) due to the convergence problems when
estimating relative risk with the complex mixed-effects models. To assess for the possibility of
the ORs overestimating the strength of association, a sensitivity analysis was conducted using
unadjusted and adjusted RRs and accompanying 95% CIs using generalized linear (GENMOD)
models.
RESULTS
Eighteen LHDs received vaccine through the WV Pilot Project, of which 10 LHDs, representing
counties from across the state, had participant forms available for inclusion in the study. A total
of 1,428 at-risk adults received at least one dose of HBV vaccine through the WV Pilot Project.
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Of the 1,428 participants, 191 started the series at a location other than the LHD or were fully
immunized per immunization records, 24 had lab results consistent with past or present HBV
infection, and 12 were vaccinated at multiple sites or their forms could not be located. Overall,
1,201 participants met the inclusion criteria and were included in the analyses with the number of
study eligible participants vaccinated through each LHD ranging from 26 to 441. (Figure 2.1 &
Supplementary Table 2.1).
A description of the number of participants vaccinated through each of the ten LHDs by setting
type can be found in Supplementary Table 2.1. Nine LHDs vaccinated participants through their
on-site STD clinics, eight vaccinated participants in ‘other’ on-site LHD clinics, and two
vaccinated women through on-site LHD family planning clinics. Half of the LHDs vaccinated
participants through partnerships with local substance use treatment centers and six collaborated
with local correctional facilities.
The majority of participants were vaccinated through LHD STD clinics (46%) or LHD outreach
to substance use treatment centers (27.6%) (Table 2.1). Over half were male (54.5%) and most
self-identified their race as white (85%). Approximately three-quarters of participants were
between 18 and 39 years of age with almost equal numbers in the 18 to 29 (37%) and 30 to 39
(36.7%) age groups.
Thirty-six percent of participants received all three doses of the HBV vaccine series and 64.4%
received at least two doses (Supplementary Table 2.2). While the majority were vaccinated at
LHD STD clinics (46%), the highest percentage of three-dose completion occurred among those
vaccinated at LHD family planning clinics (63.3%) and through LHD outreach to substance use
treatment centers (41.6%). Additionally, the highest percentage of those receiving at least two
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doses were documented at LHD family planning clinics (85.7%), correctional facilities (80.9%),
and substance use treatment centers (72%).
Primary and Secondary Objectives, Unadjusted
For the primary objective, participants vaccinated at substance use treatment centers (uOR: 1.34;
95% CI: 1.02-1.78) and LHD family planning clinics (uOR: 3.25; 95% CI: 1.77-5.97) were
significantly more likely to complete the three-dose HBV vaccine series compared to those
vaccinated at LHD STD clinics (Table 2.2). Participants vaccinated through other LHD clinics
(uOR: 0.53; 95% CI: 0.34-0.82) were significantly less likely to receive three doses. Women
(uOR: 1.43; 95% CI: 1.13-1.81) and participants ages 30 to 39 (uOR: 1.34; 95% CI: 1.01-1.78),
40 to 49 (uOR: 2.13; 95% CI: 1.48-3.08), and 50 and older (uOR: 2.21; 95% CI: 1.50-3.24) were
all significantly more likely to complete the three-dose series.
For the secondary objective, participants vaccinated at substance use treatment centers (uOR:
1.90; 95% CI: 1.42-2.55), correctional facilities (uOR: 3.12; 95% CI: 1.98-4.91), and LHD
family planning clinics (uOR: 4.43; 95% CI: 1.96-10.04) were all significantly more likely to
receive at least two doses of HBV vaccine compared to those vaccinated at LHD STD clinics.
Again, women (uOR: 1.37; 95% CI: 1.08-1.75) were significantly more likely to receive at least
two doses while participants self-identifying as African American (uOR: 0.82; 95% CI: 0.690.98) were less likely to receive at least two doses.
Primary and Secondary Objectives, Adjusted
In the multivariable logistic regression model, after controlling for sex, age, and race,
participants vaccinated at substance use treatment centers (aOR: 1.37; 95% CI: 1.01-1.86) and
LHD family planning clinics (aOR: 3.74; 95% CI: 1.98-7.06) were more likely to complete the
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three-dose series while those vaccinated at other LHD clinics (aOR: 0.38; 95% CI: 0.23-0.61)
were significantly less likely to complete the three-dose series (Table 2.3). In this model, older
age remained significantly associated with three-dose completion.
For the secondary outcome, participants vaccinated through substance use treatment centers
(aOR: 1.79; 95% CI: 1.31-2.44), correctional facilities (aOR: 3.34; 95% CI: 2.09-5.34), and LHD
family planning clinics (aOR: 3.97; 95% CI: 1.72-9.16) were significantly more likely to receive
at least two doses. Once again, women (aOR: 1.44; 95% CI: 1.11-1.86) and participants ages 50
and older (aOR: 1.83; 95% CI: 1.20-2.78) were also more likely to receive at least two doses in
the full model.
Primary and Secondary Objectives, Adjusted and Controlling for LHD
In the mixed-effects model, after controlling for the LHD as a random effect and sex, age, and
race as fixed effects, participants vaccinated at substance use treatment centers (aOR: 1.73; 95%
CI: 1.20-2.50) and LHD family planning clinics (aOR: 3.51; 95% CI: 1.63-7.56) were
significantly more likely to receive three doses compared to those vaccinated at LHD STD
clinics (Supplementary Table 2.3). In this model, older age remained significantly associated
with three-dose completion.
For the secondary objective, participants vaccinated at substance use treatment centers (aOR:
2.12; 95% CI: 1.46-3.09), correctional facilities (aOR: 2.94; 95% CI: 1.74-4.96), and LHD
family planning clinics (aOR: 4.88; 95% CI: 1.87-12.72) were significantly more likely to
receive at least two doses of HBV vaccine. Women (aOR: 1.51; 95% CI: 1.11-2.06) and
participants ages 50 and older (aOR: 1.88; 95% CI: 1.18-3.01) were also significantly more
likely to receive at least two doses.
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Sensitivity Analysis
Unadjusted and adjusted RR estimates were compared with the calculated OR. In general, the
OR closely approximated the RR. Given the OR and RR gave similar results that remained
significant across both estimates, the OR were deemed an acceptable measure of association for
this retrospective cohort study.
DISCUSSION
This is the first study to evaluate the impact of setting on completion of the HBV vaccine series
among at-risk individuals vaccinated through WV LHDs, either at their own clinics or through
expanded vaccine delivery partnerships in locations serving at-risk adults. In this study, we
found LHD family planning clinics and LHD outreach to substance use treatment centers were
associated with increased odds of receiving all three doses as well at least two doses of HBV
vaccine compared to LHD STD clinics. Additionally, participants vaccinated through LHD
outreach to correctional facilities were more likely to receive at least two doses. Differences in
receiving either two or three doses between sites most likely reflects the vaccine delivery setting
and the potential for continued future interactions with participants. People attending LHD STD
clinics may only have a single visit, while women attending a family planning clinic are likely to
return at least once a year or more. Substance use treatment centers and correctional facilities are
also settings where clients are likely to have sustained interactions with program staff.
Both in WV and nationally the greatest number of participants were reached through STD
clinics, but the proportion of participants receiving all three doses were low [4]. While STD
clinics provide a way to initiate the HBV vaccine series in many at-risk adults, series completion
remains a challenge in this setting. The use of electronic medical records and immunization
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information systems can potentially generate automatic reminders and flag client charts so staff
can contact individuals for return visits to complete the vaccine series.
In 2016, the three most common risk factors among people with acute HBV infection in WV
were injection drug use, street drug use, and incarceration [13]. The percentage of participants
receiving at least two doses through LHD outreach at correctional facilities including drug court
(81%) and substance use treatment centers (72%) indicates that ongoing LHD partnerships with
these settings might facilitate their ability to reach more at-risk individuals who need hepatitis B
vaccination due to a history of substance misuse or injection drug use. Harm reduction programs
across the state also provide another venue to reach these high-risk individuals. LHDs manage
the majority of harm reduction programs in WV: the first LHD syringe services program opened
in late 2015 and as of 2020, 16 LHDs offer harm reduction services including testing for IDUrelated infections and HBV vaccination [14]. Given the risk factors for acute HBV infection in
WV, targeting HBV vaccination efforts through substance use treatment centers, correctional
facilities, and harm reduction programs, in conjunction with use of the new two-dose Heplisav-B
vaccine, would provide protection to a greater number of those with the highest risk of hepatitis
B in a shorter period.
A notable finding of this study is that women were significantly more likely to receive all three
and just two doses compared to men. This, in combination with the increased odds of completion
among family planning clinic participants, has important implications for preventing new
hepatitis B infections in women of reproductive age. A recent study using national data from
Quest Laboratories found a significant increase in the number of reproductive age women in WV
testing positive for anti-HBc, a marker of past or current HBV infection [15]. Although the odds
of completing the series were highest among LHD family planning clinic participants, the
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number of women reached was relatively small compared to other settings. Future vaccination
efforts should include screening LHD family planning participants for hepatitis B risk factors.
Women with risk factors, or those requesting STD screening as part of their family planning
appointment, should be offered testing and vaccination.
Overall, completion of the second and third doses were higher in WV compared to other CDC
awardees. In WV, of those who received the first dose, 59% received the second dose, and 32%
received all three doses [4]. Completion of the second and third doses for the six primarily urban
CDC Pilot Program awardees with available data were 40% and 22% respectively [4]. The
success of the WV Pilot Project may be due in part to the important role LHDs play in rural
communities where healthcare access is limited. However, due to limited staff and associated
vaccine/program costs, the WV LHDs were unable to sustain the WV Pilot Project activities
after its conclusion in 2015. Expansion of Medicaid through the Affordable Care Act, along with
the increased ability of LHDs to bill for services, may allow for provision of testing and HBV
vaccination without additional cost to the client or LHDs in West Virginia.
Potential limitations
Both a strength and a limitation of this study is the inclusion of participant level data from ten of
the 18 LHDs participating in the WV Pilot Project. The ten LHDs included counties from across
the state, thus increasing the generalizability of findings; on the other hand, despite broad
geographic representation, data were only available for 56% of the participating LHDs. Another
potential limitation of this study is that data were not collected for research purposes, and the
quality of the data varied among sites. To help overcome this limitation, settings where vaccine
was administered were standardized across the LHDs, but there is still potential for
misclassification bias.
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CONCLUSION
The WV Pilot Project provided over 10,000 doses of HBV vaccine to adults considered at risk of
hepatitis B infection. Targeting vaccine delivery in settings outside of the LHD STD clinic may
increase vaccine dose completion in WV, thus resulting in more at-risk adults protected against
HBV infection. Given that substance misuse and incarceration are the most common risk factors
among people with acute HBV infection in WV, future LHD hepatitis B vaccine interventions
should prioritize testing and vaccinating in settings serving high-risk adults including substance
use treatment centers, correctional facilities, and harm reduction programs.
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Figure 2.1. Flow chart of sample selection process
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Table 2.1. Setting type and demographics of WV Pilot Project participants and primary and secondary outcomes
All subjects
Variable
N
Setting type
LHD - STD
clinic
LHD outreach to
substance use
treatment center
LHD outreach to
correctional
facility
LHD - other
clinicc
LHD - family
planning clinic

Primary outcome
Received 3 dosesa

Secondary outcome
Received at least 2 dosesa

n (%)
1201

Yes
432
(36.0)

No
769
(64.0)

p-valueb

Yes
773 (64.4)

No
428 (35.6)

p-valueb

546 (46.0)

189
(34.6)
138
(41.6)

357
(65.4)
194
(58.4)

<0.001

314 (57.5)

232 (42.5)

<0.001

239 (72.0)

93 (28.0)

141 (11.7)

45
(31.9)

96
(68.1)

114 (80.9)

27 (19.1)

133 (11.1)

29
(21.8)
31
(63.3)

104
(78.2)
18
(36.7)

64 (48.1)

69 (51.9)

42 (85.7)

7 (14.3)

211
(32.2)
221
(40.5)

444
(67.8)
325
(59.5)

0.003

400 (61.1)

255 (38.9)

373 (68.3)

173 (31.7)

128
(28.9)
155
(35.3)

315
(71.1)
284
(64.7)

<0.001

267 (60.3)

176 (39.7)

292 (66.5)

147 (33.5)

332 (27.6)

49 (4.1)

Sex
Male

655 (54.5)

Female

546 (45.5)

Age
18-29 yrs

443 (37.0)

30-39 yrs

439 (36.7)

0.009

0.172
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40-49 yrs

168 (14.1)

50+

146 (12.1)

78
(46.4)
69
(47.3)

90
(53.6)
77
(52.7)

113 (67.3)

55 (32.7)

97 (66.4)

49 (33.6)

Race
White, missing,
1093 (91.0)
396
697
0.55
715 (65.4)
& other
(36.2)
(63.8)
African
108 (9.0)
36
72
58 (53.7)
American
(33.3)
(66.7)
a
Outcome variables are reported as the percentage relative to the row attribute

378 (34.6)

0.015

50 (46.3)

3

b

p-value for Chi-squared test statistic. Abbreviations: STD =sexually transmitted disease; LHD = local health department

4

c

Includes participants vaccinated in LHD clinics other than STD and family planning

5

Note: Boldface indicates statistical significance (p<0.05).
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Table 2.2. Unadjusted odds ratios for exposure variables and primary and secondary objectives

Variable
Setting type
LHD - STD clinic
LHD outreach to substance
use treatment center
LHD outreach to
correctional
facility
LHD - other clinica
LHD - family planning
clinic

Primary objective
Received 3 doses
uOR
95% CI
p-value

Secondary objective
Received at least 2 doses
uOR
95% CI
p-value

1
1.34

(1.02-1.78)

0.039

1
1.90

(1.42-2.55)

<0.001

0.89

(0.60-1.32)

0.547

3.12

(1.98-4.91)

<0.001

0.53
3.25

(0.34-0.82)
(1.77-5.97)

0.005
<0.001

0.69
4.43

(0.47-1.00)
(1.96-10.04)

0.05
<0.001

0.003

1
1.37

(1.08-1.75)

0.009

0.042
<0.001
<0.001

1
1.31
1.35
1.31

(1.00-1.72)
(0.93-1.97)
(0.88-1.93)

0.055
0.112
0.184

Sex
Male
Female

1
1.43

Age
18-29 yrs
30-39 yrs
40-49 yrs
50+

1
1.34
2.13
2.21

(1.13-1.81)

(1.01-1.78)
(1.48-3.08)
(1.50-3.24)

Race
White, missing, & other
1
1
African American
0.88 (0.58-1.34)
0.549
0.61
(0.41-0.91)
Abbreviations: STD =sexually transmitted disease; LHD = local health department.
a

0.016

Includes participants vaccinated in LHD clinics other than STD and family planning

Note: Boldface indicates statistical significance (p<0.05).
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Table 2.3. Adjusted odds ratios for exposure variables and primary and secondary objectives

Variable
Setting type
LHD - STD clinic
LHD outreach to
substance use treatment
center
LHD outreach to
correctional
facility
LHD - other clinica
LHD - family planning
clinic

Primary outcome
Received 3 doses
aOR
95% CI
p-value

Secondary outcome
Received at least 2 doses
aOR
95% CI
p-value

1
1.37

(1.01-1.86)

0.041

1
1.79

(1.31-2.44)

<0.001

0.91

(0.60-1.39)

0.6622

3.34

(2.09-5.34)

<0.001

0.38
3.74

(0.23-0.61)
(1.98-7.06)

<0.001
<0.001

0.58
3.97

(0.39-0.87)
(1.72-9.16)

0.008
0.001

0.069

1
1.44

(1.11-1.86)

0.006

0.027
<0.001
<0.001

1
1.21
1.39
1.83

(0.91-1.62)
(0.94-2.05)
(1.20-2.78)

0.196
0.102
0.005

Sex
Male
Female

1
1.28

Age
18-29 yrs
30-39 yrs
40-49 yrs
50+

1
1.40
2.57
3.38

(0.98-1.66)

(1.04-1.89)
(1.76-3.77)
(2.23-5.13)

Race
White, missing, & other
1
African American
0.92 (0.59-1.44)
0.729
0.78 (0.52-1.19)
Abbreviations: STD =sexually transmitted disease; LHD = local health department.
a

0.254

Includes participants vaccinated in LHD clinics other than STD and family planning

Note: Boldface indicates statistical significance (p<0.05).
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Supplementary Table 2.1. Number of WV Pilot Project participants vaccinated through each
local health department by setting type
Setting type
Local Health
LHD - STD LHD outreach LHD
LHDa LHD Department
clinic
to substance
outreach to
other
family
use treatment
correctional
clinic
planning
centers
facilities
clinic
1
194
157
90
2
86
60
36
6
3
74
21
6
43
4
21
71
11
4
5
63
10
5
6
22
7
39
7
35
17
16
8
23
24
9
27
7
10
24
2
Total participants
546
332
141
133
49
Total setting type
9
5
6
8
2
a
Includes participants vaccinated in LHD clinics other than STD and family planning

Total
participants

441
188
144
107
78
68
68
47
34
26
1201

Supplementary Table 2.2. Frequency and percentage of doses received by WV Pilot Project
setting type
Setting type

1 dose
n
546
332

2 doses*
n (%)
314 (57.5)
239 (72.0)

3 doses**
n (%)
189 (34.6)
138 (41.6)

LHD - STD clinic (n=9)
LHD outreach to substance use
treatment center (n=5)
LHD outreach to correctional
141
114 (80.9)
45 (31.9)
facility (n=6)
LHD – other clinica (n=8)
133
64 (48.1)
29 (21.8)
LHD - family planning clinic (n=2)
49
42 (85.7)
31 (63.3)
Total participants
1201
773 (64.4)
432 (36.0)
*Those receiving dose one who received dose two, **those receiving dose one who received
dose three. Abbreviations: STD =sexually transmitted disease; LHD = local health department.
a

Includes participants vaccinated in LHD clinics other than STD and family planning
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Supplementary Table 2.3. Mixed-effects model adjusted odds ratios controlling for local health
department as a random effect

Variable
Setting type
LHD - STD clinic
LHD outreach to
substance use treatment
center
LHD outreach to
correctional
facility
LHD - other clinica
LHD - family planning
clinic

aOR

Primary outcome
Received 3 doses
95% CI
p-value

Secondary outcome
Received at least 2 doses
aOR
95% CI
p-value

1
1.73

(1.20-2.50)

0.006

2.12

(1.46-3.09)

<0.001

0.93

(0.57-1.50)

0.737

2.94

(1.74-4.96)

<0.001

0.56
3.51

(0.30-1.01)
(1.63-7.56)

0.054
0.003

0.74
4.88

(0.44-1.23)
(1.87-12.72)

0.221
0.003

Sex
Male
Female

1
1.32

(0.97-1.81)

0.075

1.51

(1.11-2.06)

0.014

Age
18-29 yrs
30-39 yrs
40-49 yrs
50+

1
1.50
2.64
3.23

(1.09-2.07)
(1.74-4.00)
(2.03-5.14)

0.015
<0.001
<0.001

1.31
1.45
1.88

(0.96-1.79)
(0.95-2.22)
(1.18-3.01)

0.086
0.084
0.01

Race
White, missing, & other
1
1
African American
1.01
(0.63-1.61)
0.971
0.82
(0.53-1.28)
Abbreviations: STD =sexually transmitted disease; LHD = local health department.
a

0.389

Includes participants vaccinated in LHD clinics other than STD and family planning

Note: Boldface indicates statistical significance (p<0.05).
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CHAPTER THREE
Factors Associated with Hepatitis B Exposure among People who Report Using
Methamphetamine: NHANES 2009-2016

Tressler SR, Kushner T, Bhandari R. Factors Associated With Hepatitis B Exposure Among
People Who Report Using Methamphetamine: National Health and Nutrition Examination
Survey 2009–2016, J Infect Dis 2020; 221(2):243–250.

ABSTRACT
Background: With the nation’s focus on the opioid crisis, methamphetamine has made a
comeback, potentially increasing risk for hepatitis B. We examined factors associated with
hepatitis B virus (HBV) exposure among people who reported ever using methamphetamine in a
nationally representative survey.
Methods: We utilized the National Health and Nutrition Examination Survey to examine factors
associated with HBV exposure among participants who reported ever using methamphetamine
using bivariate and multivariable logistic regression.
Results: Overall, 847 participants met the study inclusion criteria. In multivariable logistic
regression, female sex (aOR 3.83, 95% CI 1.65 – 8.90), living below the poverty threshold (aOR
3.17, 95% CI 1.39 – 7.21), injection drug use (IDU) (aOR 4.89, 95% CI 1.95 – 12.26), active
hepatitis C (HCV) infection (aOR 3.39, 95% CI 1.10 – 12.26), and identifying as men who have
sex with men (aOR 28.21, 95% CI 5.19 – 153.38) were significantly associated with HBV
exposure.
Conclusions: The odds of HBV exposure for females who reported using methamphetamine was
four times higher than males. Poverty, IDU, and HCV infection were also associated. As
methamphetamine use increases, it is critical to identify those at risk of acquiring HBV
infections in order to target testing and vaccination.
Keywords: Methamphetamine; hepatitis B; NHANES
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INTRODUCTION
Hepatitis B is a significant public health problem worldwide with over 350 million chronic
carriers globally, and an estimated 850,000 to 2.2 million individuals in the U.S. [1-3]. Although
the leading cause of chronic infection worldwide is through vertical transmission, in the U.S., the
most common mode of transmission is horizontal. Hepatitis B virus (HBV) is spread through
contact with blood and body fluids and is highly infectious. Acute infection can progress to
lifelong chronic infection with younger age at time of transmission being the greatest factor in
progression to chronicity [4]. About 50% of people chronically infected are unaware of their
infection and remain a source of ongoing transmission [5].
In the U.S., the incidence of acute hepatitis B infections has decreased 75% over the past three
decades largely due to the implementation of universal vaccination of infants at birth in 1991 and
the recommendation for catch-up vaccination of adolescents in 1997 [6, 7]. Due in part to low
rates of hepatitis B nationwide, attention has centered on transmission and prevention of HIV
and HCV in high-risk groups. As recently as 2006, the rate of acute HBV infections in the U.S.
has remained stable at around 1 case per 100,000 people [8]. However, over the past decade,
opioid misuse and injection drug use (IDU) has resulted in a resurgence in cases of acute
hepatitis B [9, 10].
Nationwide, in 2015 the highest incidence of acute HBV infections occurred among persons 30
to 39 years of age with 30% of newly infected people reporting IDU as a risk factor [11]. Most
notably, there was a substantial increase in acute HBV cases in parts of Appalachia including
Kentucky, Tennessee, and West Virginia. From 2009-2013, there was a 114% increase in the
number of newly reported acute infections in these three states [8]. The majority of the cases
occurred among non-Hispanic whites, 30 to 39 years of age with 75% reporting IDU as a risk
factor [8].
With the nation’s focus on the opioid crisis, methamphetamine has made a largely unnoticed
comeback. Methamphetamine use in the U.S. peaked around 2005 but has reemerged as a threat
in recent years accounting for 11% of overdose deaths in 2016 [12, 13]. Nationwide use has
increased along with reported co-use with opioids [12]. A recent study found methamphetamine
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use almost doubled from 18.8% in 2011 to 34.2% among people using opioids who sought
treatment in the U.S. in 2017 [14]. The increase in methamphetamine use and co-use with
opioids represents a public health threat requiring a refocusing of response efforts.
Methamphetamine is a potent stimulant that can be smoked, injected, snorted, or taken orally
[15]. People who use methamphetamine either through injection or non-injection routes are at an
increased risk for acquiring sexually transmitted infections including hepatitis B [15]. For people
who inject methamphetamine, HBV can be acquired through sharing of needles as well as
injecting equipment, and sexual practices. Outbreaks of hepatitis B among people who inject
methamphetamine have been documented [16, 17]. A study by Vogt et al. (2006) found an
association between sharing equipment used to inject methamphetamine, including rinse water
and cotton filters, and HBV infection [16]. More recently, methamphetamine has been
implicated in a ten-fold increase in acute hepatitis B cases, as well as an increase in hepatitis C,
HIV, and syphilis in Winnipeg, Canada [18].
Hepatitis B remains a real and ongoing threat to a number of high-risk groups, including people
who use drugs and those engaging in high-risk sexual behaviors. It is recommended that highrisk people without serological evidence of HBV infection or immunity be vaccinated against
HBV [10]. As methamphetamine use and co-use with opioids increase, it is important to
understand the risk factors associated with HBV exposure among this population to help guide
education, testing, and vaccination efforts.
In this study, we examined factors associated with hepatitis B exposure among people who
reported ever using methamphetamine in the National Health and Nutrition Examination Survey
(NHANES) [19].
METHODS
The study population included NHANES participants who answered “yes” to ever using
cocaine/heroin/methamphetamine, and subsequently “yes” to using methamphetamine from 2009
to 2016 and completed testing for HBV. Participants under the age of 18 and older than 69 were
not eligible to answer this question and were excluded from this study. Participants with
serological evidence of HBV immunity from vaccination were also excluded from the study (see
Figure 3.1).
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Study design
NHANES is a cross-sectional survey conducted by the Centers for Disease Control and
Prevention’s (CDC) National Center for Health Statistics (NCHS) to assess health and nutritional
status of the U.S. population [19]. Data are collected over a two-year period and include
participant interviews accompanied by physical examinations and laboratory specimen
collection. Participants are selected using a complex, multistage, probability sampling design that
is representative of U.S. noninstitutionalized civilian population living in the 50 states and the
District of Columbia. NHANES data are publicly available for research purposes.
Outcome variable
The outcome variable, exposure to HBV, was defined as a positive result to total hepatitis B core
antibody (anti-HBc), a marker of past or present infection with hepatitis B. Susceptibility to
HBV was defined as being negative for all HBV lab markers including anti-HBc, hepatitis B
surface antigen (HBsAg), and hepatitis B surface antibody (HBsAb). Participants with
serological evidence of vaccine-induced immunity, defined as being solely HBsAb positive,
were excluded.
Exposure variables
Exposure variables known to be associated with hepatitis B exposure were chosen based on
previous studies and availability in the NHANES dataset. For the frequency of
methamphetamine use and questions on sexual identity and partners, only participants 18 to 59
years old were eligible to answer. Classifications for each variable can be found in Table 3.1.
Hepatitis C status was coded as positive, negative, or missing. Negative was defined as antibody
negative, or antibody positive but subsequently testing RNA negative. Positive was defined as
confirmed to be RNA positive after a positive antibody test indicating an active HCV infection.
Lab markers for HIV, HSV 2, and syphilis were not included due to small sample size and
inability to combine due to differences in age groups tested. Indeterminate lab results were coded
as missing.
Data analysis
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SAS version 9.4 was used for all analyses. Survey procedures including SURVEYFREQ and
SURVEYLOGISTIC were used to account for complex survey design in the analysis.
SDMVSTRA was used in the strata statements and SDMVPSU in the cluster statements.
Weighted frequencies and standard errors for the combined eight years of data were calculated
by multiplying the sample weight WTMEC2YR by 1/4. A subcategory including only
participants who completed the medical exam and answered ‘yes’ to ever using
methamphetamine was included at the beginning of each table statement when calculating
frequencies and in the domain statement for logistic regression. For all analyses, confidence
intervals (CI) that did not cross one and a p-value less than .05 were considered statistically
significant.
Descriptive statistics, weighted percentages, and weighted frequencies were calculated for all
variables. The Rao Scott Chi-squared statistic was calculated to assess the relationship between
each exposure variable and HBV exposure. Bivariate logistic regression was used to calculate the
unadjusted odds ratio (uOR) and 95% CI for each exposure variable and HBV exposure. Three
multivariable logistic regression models were used to calculate the adjusted odds ratios (aOR)
and 95% CI for the exposure variables and HBV exposure. Model 1 examined the association of
demographic variables (sex, age, and race/ethnicity) with the outcome among participants 18-69
years. Model 2 built on Model 1 and examined the association of poverty index, health
insurance, IDU, and HCV status in addition to the demographic variables in Model 1 among
participants 18-69 years. Model 3 adjusted for all exposure variables but only included
participants 20 to 59 years old due to age restriction for answering the following questions:
education (20 years and older), number of times used methamphetamine (18 to 59 years old),
sexual identity (18 to 59 years old), and number of sex partners in the past year (18 to 59 years
old). A missing category was created for each exposure variable with missing data and was
included in the analyses.
A sensitivity analysis was performed on missing values for question DUQ240 – Have you ever
used cocaine/heroin/methamphetamine - to examine differences in missing data by sex, age, and
race/ethnicity.
RESULTS
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A total of 40,439 people participated in NHANES from 2009 through 2016. Out of the total
participants who reported ever using methamphetamine and completed HBV testing, 5.6% were
exposed to HBV, 15.1% had vaccine-induced immunity, and almost 80% were susceptible to
HBV infection. Of those exposed to HBV, 6.4% were HBsAg positive indicating an active
hepatitis B infection. After excluding those with vaccine-induced immunity, 6.6% of participants
who reported ever using methamphetamine had lab markers consistent with HBV exposure and
93.4% were susceptible to HBV infection. Overall, 847 participants reported ever using
methamphetamine and were either exposed or susceptible to hepatitis B and thus eligible for
inclusion in the study (see Figure 3.1).
Frequencies and weighted estimates for exposure variables and the HBV exposure can be found
in Table 3.1. Based on the weighted estimate, the 847 participants represented approximately
11,048,115 people in the U.S. All reported percent estimates and standard errors are calculated
from the weighted frequencies.
In the study sample, the majority of participants were male (68.3%) and approximately, threequarters of participants were between 30 to 59 years of age, with the greatest proportion in the 50
to 59 age range (30.8%). Most participants were non-Hispanic white (77.5%) and living at or
above twice the poverty index (58.6%). While only 15% of participants were categorized as
living below the poverty index threshold, they comprised over one-third of those exposed to
HBV (35.4%). Nearly three-quarters of participants reported having some type of health
insurance (73.1%) and education attainment as high school, GED, or higher. About a fifth
reported ever injecting drugs (20.2%) but they accounted for over half of those exposed to HBV
(56.7%). While only 7% had an active HCV infection they accounted for 28.5% of those exposed
to HBV. Almost an equal number of participants reported using methamphetamine ≤ to 5 times,
6 to 49 times, and ≥ 50 times. Of those exposed to HBV 42.5% reported using methamphetamine
≥ 50 times. The majority of participants self-identified as heterosexual (80.7%) and reported less
than 2 sexual partners in the past year (65.8%).
Table 3.2 presents the unadjusted odds ratios (uOR) and 95% CIs for each exposure variable and
the outcome variable. Among those who reported using methamphetamine, being female was
significantly associated with exposure to HBV (uOR 2.11, 95% CI 1.05 - 4.26), as was being
non-Hispanic black (uOR 2.63, 95% CI 1.30 - 5.3), living below the poverty threshold (uOR
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3.73, 95% CI 1.93 – 7.21), IDU (uOR 6.28, 95% CI 2.77- 14.26), active HCV infection (uOR
7.07, 95% CI 3.24 – 15.44), using methamphetamine ≥ 50 times (5.01, 95% CI 1.88 – 13.35),
and identifying as MSM (uOR 6.33, 95% CI 1.81 – 22.14).
Adjusted odds ratios (aOR) and 95% CIs were calculated in models 1, 2, and 3. The results of
each model can be found in Table 3.2. After controlling for sex, age, and race/ethnicity in model
1, being female (aOR 2.18, 95% CI 1.06 – 4.51) and non-Hispanic black (aOR 2.37, 95% CI
1.09 – 2.31) were significantly associated with exposure to HBV. After adding poverty index,
health insurance, IDU, and HCV status, there was a significant association between being female
(aOR 2.54, 95% CI 1.27 – 5.07), 60 to 69 years old (5.67, 95% CI 1.04 – 30.96), living below the
poverty threshold (aOR 3.14, 95% CI 1.47 – 6.74), IDU (aOR 4.82, 95% CI 2.05 – 11.31), and
active HCV infection (aOR 2.85, 95% CI 1.05 – 7.78). In model 3, after adjusting for all
exposure variables there was a significant association between being female (aOR 3.83, 95% CI
1.65 – 8.90) and exposure to HBV, as well as living below the poverty threshold (aOR 3.17, 95%
CI 1.39 – 7.21), IDU (aOR 4.89, 95% CI 1.95 – 12.26), active HCV infection (aOR 3.39, 95% CI
1.10 – 12.26), and identifying as MSM (aOR 28.21, 95% CI 5.19 – 153.38).
To answer methamphetamine specific questions, participants had to answer ‘yes’ to ever using
cocaine, heroin, or methamphetamine. Missing data for this inclusion question were examined.
Among all participants, 19,998 were eligible to answer the question and data were missing for
2,587 (12.9%) participants. The odds of missing values were higher for females, younger
participants, non-Hispanic blacks, and other races. All odds ratios indicated weak associations
between missing values and the demographic variables. Based on these findings selection bias
did not appear to be a factor.
DISCUSSION
In this study, eight years of NHANES data were evaluated in order to provide estimates of the
U.S. non-institutionalized population representing over 11 million people who reported ever
using methamphetamine. The use of lab markers provided accurate estimates of hepatitis B
exposure and hepatitis C infection in this population. Compared to the overall study population
who reported ever using methamphetamine, a disproportionate amount of the HBV exposed
group comprised of females, persons with active HCV infection, MSM, participants 50 to 69
years old (baby boomers), participants living below the poverty threshold, and those reporting
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IDU. In bivariate analysis, the odds of HBV exposure among those who reported using
methamphetamine ≥ 50 times was five times higher compared to those who used ≤ 5 times,
suggesting an increased odds of exposure with increased use. In the full model, four of the
significant associations were consistent with previously identified risk factors for acquiring
hepatitis B infection, including living below the poverty threshold, IDU, active HCV infection,
and self-identifying as MSM [4, 20]. Also, being female was significantly associated with HBV
exposure. After adjusting for all co-variates, the odds of hepatitis B exposure for females who
reported using methamphetamine was nearly four times higher compared to males. Interestingly,
in this study, reporting multiple sexual partners was not associated with hepatitis B exposure.
This result was unexpected considering high-risk sexual practices, including multiple sexual
partners, is associated with both methamphetamine use and hepatitis B infection. However, while
methamphetamine use was reported as ever having used in lifetime, the number of sexual
partners was only reported for the previous year.
Nationwide, an increase in HCV infection among reproductive age women and a rise in babies
born with neonatal abstinence syndrome indicates increased drug use among women in general
[21, 22]. In light of the 2019 MMWR study highlighting the increase in methamphetamine use
among females with primary and secondary syphilis, the results from this study suggest a similar
pattern for HBV exposure in females using methamphetamine [23]. Additionally, a study
analyzing hospital delivery data from 2004 to 2015 found an increasing trend of amphetamine
use among women delivering a baby; amphetamine use was reported in 2.4 per 1,000 hospital
deliveries in 2014 to 2015 [24].
Some of the exposures identified in this study were consistent with previous studies; however,
the significant association between females who reported methamphetamine use and HBV
exposure suggests increased efforts may be needed for this population subgroup. These findings
highlight the importance of screening for substance use including methamphetamine, as well as
testing and vaccinating for HBV among reproductive-age women to prevent mother-to-child
transmission of HBV during pregnancy. The U.S. Preventive Services Task Force recently
reaffirmed their recommendation that all pregnant women be screened for HBV at the first
prenatal visit highlighting the important role of obstetrician-gynecologists in providing primary
care including HBV screening and vaccination [25]. Additionally, harm reduction programs
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provide another avenue to reach high-risk individuals, including women, who may not access
primary care services.
NHANES is a cross-sectional study design and temporality between risk factors and HBV
exposure cannot be established. It is not possible to know if HBV exposure occurred as a result
of methamphetamine use or if use is a potential marker for other high-risk behaviors.
Additionally, a relatively small sample size and subcategories used in analyses resulted in a
number of wide confidence intervals and these results should be interpreted with caution.
Participants were included in the study if they reported ‘ever using’ methamphetamine. The
sensitive nature of questions regarding drug use and sexual behavior may result in people not
answering certain questions or not answering accurately resulting in incorrect estimates arising
from potential non-response or misclassification bias. However, these questions were selfadministered using an Audio Computer-Assisted Self Interview system in a private room during
the medical exam component of the survey, which may have resulted in participants feeling more
comfortable to respond truthfully. Finally, susceptibility to HBV was determined as the absence
of all HBV lab markers, including anti-HBs. In vaccinated persons, anti-HBs wanes over time,
therefore some participants included in the susceptible comparison group may have vaccineinduced immunity with anti-HBs levels below detectable levels. NHANES data do not include
incarcerated or homeless individuals; this may affect the generalizability of results to the entire
U.S. population.
CONCLUSION
As methamphetamine use continues to rise, it is important to identify those at highest risk of
acquiring hepatitis B infections in order to target testing and vaccination programs. The
estimated number of susceptible participants who reported using methamphetamine in this study
suggests a need to provide targeted vaccination efforts in this potentially at-risk population.
Harm reduction programs should incorporate testing for HBV and vaccination to help reduce the
disease burden among this high-risk group. Additionally, the results from this study indicates a
need to target not only high-risk individuals but also older individuals who may not have
benefited from the HBV birth dose or adolescent catch-up vaccination. Finally, the association of
HBV exposure with active HCV infection suggests shared risk factors and efforts for HBV
prevention can potentially be incorporated with existing efforts to reduce HCV transmission.
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Figure 3.1 Flow chart of sample size selection – NHANES, 2009-2016
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Table 3.1 Descriptive statitics, weighted percents, weighted frequencies, and standard errors for exposure variables and HBV status
All subjects
Variable

n

Weighted
frequency (SE)

N

847

11,048,115
(752,495)

Sex
Male

570

7,550,294
(545,825)
3,497,821
(309,494)

Female

277

Age
18-29 yrs

94

30-39 yrs

205

40-49 yrs

224

50-59 yrs

214

60-69 yrs

110

Race or ethnicity
Non-Hispanic White

514

Non-Hispanic Black

70

Hispanic/Other

263

Exposed to HBV
Weighted
% (SE)

Susceptible to HBV

n

Weighted
% (SE)

n

Weighted
% (SE)

71

6.60
(1.15)

776

93.40
(1.15)

68.34
(1.75)
31.66
(1.75)

41

51.93
(8.11)
48.07
(8.11)

529

69.50
(1.85)
30.50
(1.85)

0.0289

1,086,476
(134,268)
2,361,070
(219,896)
2,920,646
(273,616)
3,405,008
(401,923)
1,274,914
(185,187)

9.83
(1.12)
21.37
(1.73)
26.44
(1.77)
30.82
(2.45)
11.56
(1.50)

2

7.11
(4.76)
10.56
(4.21)
13.12
(4.60)
41.46
(6.60)
27.75
(5.97)

92

10.03
(1.24)
22.13
(1.83)
27.38
(1.85)
30.07
(2.59)
10.39
(1.34)

< 0.001

8,564,402
(723,456)
343,250
(54,965)
2,140,463
(249,211)

77.52
(2.32)
3.11
(0.53)
19.37
(2.29)

77.54
(2.34)
2.81
(0.49)
19.65
(2.31)

0.0256

30

8
10
27
24

37
13
21

77.25
(5.47)
7.35
(2.28)
15.40
(4.54)

247

197
214
187
86

477
57
242

p-value*

60

Poverty Index
Below threshold

205

1 to 1.9

245

≥ 2.0

356

Missing

41

Health Insurance
Yes
No
Injection Drug Use
No
Yes
Missing
HCV
Negative
Positive
(Active Infection)
Missing
Education
(20+ yrs)
< 12 H.S.
≥ 12 H.S. or GED

572
275

1,656,518
(186,424)
2,530,213
(300,853)
6,474,304
(560,244)
387,079
(82,035)

14.99
(1.56)
22.90
(2.00)
58.60
(2.84)
3.50
(0.78)

30

8,072,221
(594,938)
2,975,894
(272,768)

73.06
(1.77)
26.94
(1.77)

50

14
22
5

21

35.39
(6.49)
16.44
(5.94)
41.82
(7.59)
6.34
(4.17)

175

70.66
(7.52)
29.34
(7.52)

522

231
334
36

254

13.55
(1.47)
23.36
(2.05)
59.79
(2.92)
3.30
(0.77)

< 0.001

73.23
(1.87)
26.77
(1.87)

0.7392

<.0001
669
177
1

8,804,721
(607,8181)
2,234,510
(254,403)
8,884 (8,884)

79.69
(1.71)
20.23
(1.70)
0.08
(0.08)

26
44
1

42.10
(8.83)
56.68
(8.58)
1.22
(1.19)

643
133
0

82.35
(1.82)
17.65
(1.82)
N/A
<.0001

774
65
8

176
663

10,169,052
(673,644)
767,823
(139,351)
111,240
(62,835)

92.04
(1.17)
6.95
(1.13)
1.01
(0.54)

41

1,676,636
(174,344)
9,308,227
(704,975)

15.18
(1.54)
84.25
(1.58)

11

26
4

60

69.48
(6.86)
28.47
(6.90)
2.05
(1.11)

733

14.19
(5.08)
85.81
(5.08)

165

39
4

603

93.64
(1.11)
5.43
(1.03)
0.93
(0.58)

15.25
(1.61)
84.14
(1.65)

0.8320

61

Missing
Number or times used
(18-59 yrs)
≤ 5 times

8

63,252 (29,626)

0.57
(0.27)

0

N/A

8

0.61
(0.28)

227

3,297,439
(300,396)
3,305,169
(367,890)
3,155,935
(339,479)
1,289,571
(185,532)

29.85
(2.71)
29.92
(2.06)
28.57
(2.04)
11.67
(1.50)

8

9.63
(3.98)
20.08
(5.59)
42.54
(8.51)
27.75
(5.97)

219

31.28
(2.74)
30.61
(2.17)
27.58
(2.03)
10.54
(1.34)

< 0.001

8,914,926
(662,502)
323,237
(84,470)
514,367
(105,628)
1,295,585
(184,607)

80.69
(1.51)
2.93
(0.79)
4.66
(0.91)
11.73
(1.50)

57.00
(7.13)
10.47
(4.79)
4.03
(2.29)
28.50
(6.00)

628

82.37
(1.51)
2.39
(0.76)
4.70
(0.98)
10.54
(1.36)

< 0.001

6-49 times

241

≥ 50 times

267

Missing
(ages 60 to 69, n = 110)
Sexual Identity
(18-59 yrs)
Heterosexual

112

663

MSM

25

Other

46

Missing
(ages 60 to 69, n = 110)
Sex Partners in Past Year
(18-59 yrs)
<2
≥2

113

14
25
24

35
7
4
25

227
242
88

18
42
88

< 0.001
531
206

Missing
110
(ages 60 to 69, n = 110)
*p-value for Rao-Scott Chi-squared test statistic

7,265,830
(583,348)
2,507,370
(255,002)
1,274,914
(185,187)

65.77
(2.13)
22.70
(1.98)
11.54
(1.50)

33
14
24

50.53
(8.46)
21.71
(6.28)
27.75
(5.97)

498
192
86

66.84
(2.15)
22.76
(2.02)
10.39
(1.34)

HCV = Hepatitis C virus, HS = High School, GED = General Education Development, MSM = Men who have sex with men
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Table 3.2 Unadjusted and adjusted odds ratios for association between exposure variables and
HBV status

Variable
Sex
Male
Female
Age
18-29 yrs
30-39 yrs
40-49 yrs
50-59 yrs
60-69 yrs
Race or ethnicity
Non-Hispanic White
Non-Hispanic Black
Hispanic/Other
Poverty Index
Below threshold
1 to 1.9
≥ 2.0
Health Insurance
Yes
No
Injection Drug Use
No
Yes
HCV
Negative
Positive
Education (20+ yrs)
< 12 H.S.

Model 1*

Model 2 †

uOR
(95% CI)

aOR
(95% CI)

aOR
(95% CI)

Model 3 ‡
(ages 20 to 59)
aOR
(95% CI)

1
2.11
(1.05 - 4.26)

1
2.18
(1.06 - 4.51)

1
2.54
(1.27 - 5.07)

1
3.83
(1.65 - 8.90)

1
0.67
(0.12 – 3.72)
0.676
(0.13 - 3.66)
1.95
(0.39 - 9.60)
3.77
(0.76-18.72)

1
0.72
(0.13 - 3.90)
0.73
(0.13 - 3.96)
2.02
(0.39 - 10.60)
4.02
(0.80 - 20.30)

1
0.89
(0.17 - 4.77)
0.55
(0.10 0 3.03)
1.78
(0.38 - 8.42)
5.67
(1.04 - 30.96)

1
0.83
(0.10 - 6.80)
0.50
(0.07 - 3.67)
1.79
(0.23 - 13.95)
NA

1
2.63
(1.30 - 5.30)
0.786
(0.41 - 1.52)

1
2.37
(1.09 - 5.14)
1.17
(0.59 - 2.31)

1
1.53
(0.52 - 4.53)
1.01
(0.49 - 2.10)

1
1.99
(0.52 - 7.67)
0.97
(0.44 - 2.14)

3.73
(1.93 - 7.21)
1.06
(0.39 - 2.63)
1

3.14
(1.47 - 6.74)
0.98
(0.34 - 2.87)
1

3.17
(1.39 - 7.21)
0.99
(0.32 -3.06)
1

1
1.14
(0.53 - 2.45)

1
1.22
(0.46 - 3.22)

1
1.58
(0.61 - 4.01)

1
6.28
(2.77 - 14.26)

1
4.82
(2.05 - 11.31)

1
4.89
(1.95 - 12.26)

1
7.07
(3.24 - 15.44)

1
2.85
(1.05 - 7.78)

1
3.39
(1.10 - 12.26)

1

1
63

≥ 12 H.S. or GED
Number or times used
(18-59 yrs)
≤ 5 times
6-49 times
≥ 50 times
Sexual Identity
(18-59 yrs)
Heterosexual
MSM
Other

1.10
(0.46 - 2.60)

1.39
(0.31 - 6.34)

1
2.13
(0.78 - 5.79)
5.011
(1.88 - 13.35)

1
1.65
(0.54 - 5.06)
2.78
(0.67 - 11.47)

1
6.33
(1.81 - 22.14)
1.24
(0.33 - 4.71)

1
28.21
(5.19 - 153.38)
0.55
(0.07 - 4.41)

Sex Partners in Past Year
(18-59 yrs)
<2
≥2

1
1
1.262
1.19
(0.53 - 3.0)
(0.35 - 4.06)
HCV = Hepatitis C virus, HS = High School, GED = General Education Development, MSM = Men who
have sex with men
*Model 1 includes sex, age, and race/ethnicity
†

Model 2 includes sex, age, race/ethnicity, poverty index, health insurance, injection drug use, and HCV

‡

Model 3 includes sex, age, race/ethnicity, poverty index, health insurance, injection drug use, HCV,
education, number of times used, sexual identity, and sex partners in the past year
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CONCLUSION
Despite decreasing trends nationwide, WV’s rate of acute hepatitis B increased from 2002 to
2016, and was 12 times higher than the US rate in 2017 [1]. A safe and effective HBV vaccine
has existed for almost four decades, yet HBV continues to be problematic in certain at-risk
groups. Ongoing transmission indicates the need for continual efforts to identify changing
hepatitis B trends and the necessity to evaluate the effectiveness of vaccine interventions meant
to reach those most at risk. The specific aims of our three studies were to assess changes in the
acute hepatitis B in WV over the past decade, evaluate the effectiveness of vaccinating at-risk
individuals in settings outside LHD STD clinics, and understand factors associated with HBV
exposure in an emerging at-risk group of people who report using methamphetamine. Notable
findings of our research include:


A shift in the WV county-level hotspot of acute hepatitis B rate over the past decade and
a significant rate decrease in half of the WV Pilot Project counties after vaccine
distribution.



Increased odds of completing all three doses of hepatitis B vaccine at substance use
treatment centers and LHD family planning clinics as well as receipt of at least two
doses at substance use treatment centers, LHD family planning clinics, and correctional
facilities compared to WV Pilot Project participants vaccinated through LHD STD
clinics.



Higher odds of HBV exposure among women who reported using methamphetamine, as
well as those living below the poverty threshold, people with active HCV infection, men
identifying as MSM, or self-identifying as a person who injects drugs [2].

Results from our geospatial analyses can help identify areas in current need of enhanced hepatitis
B surveillance and guide placement of harm reduction services including HBV testing and
vaccination. However, ongoing geospatial analyses are needed to visualize and monitor trends
over time and test for statistically significant hotspots of HBV transmission. Additionally, unique
approaches, including Bland-Altman analysis and graphing, provide a way to evaluate HBV
prevention efforts at the county-level by visualizing significant rate differences in relation to the
WV mean difference after project implementation.
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In addition to monitoring trends in county-level data, evaluation of participant-level data is key
to understanding successful aspects of vaccination programs in at-risk group. For our WV Pilot
Project participant study, data were available for over half of the LHDs representing 1,201
participants. While most participants were vaccinated through LHD STD clinics, there were
increased odds of receiving all three doses if vaccinated through substance use treatment centers
or LHD family planning clinics. Given that IDU and street drug use are the two most commonly
reported risk factors among persons with acute HBV infection in WV, our findings indicate
vaccination services provided through partnerships between LHDs and substance use treatment
centers may result in more at-risk adults both receiving and completing the HBV series [3, 4].
Study results also indicate there were increased odds of receiving at least two doses at substance
use treatment centers, LHD family planning clinics, and correctional facilities. In 2016,
incarceration was the third most common risk factor among people with acute HBV infection
[4]. Regional jails and drug courts are another way LHDs can successfully vaccinate at-risk
individuals with either two doses of the traditional three-dose HBV series or both doses of the
new highly immunogenic Heplisav-B vaccine.
Finally, our findings indicate that people reporting methamphetamine use in a nationally
representative survey of the noninstitutionalized population, have similar factors associated with
HBV exposure as those previously identified including identifying as MSM, active HCV
infection, living below the poverty threshold, and IDU [5-7]. Based on these results, vaccination
efforts can potentially reach those at-risk by targeting groups already known to have an increased
risk of exposure. However, a notable finding of our study was the odds of HBV exposure was
four times higher in women who reported using methamphetamine compared to men. These
findings coupled with increases in HCV infections and HBV exposure among women of
childbearing age highlight the need to provide testing and vaccination to women [8-11]. Results
from the WV Pilot Project indicate that LHD family planning clinics can serve as an important
way to reach women and ensure they complete the HBV vaccine series thus protecting them and
future generations.
Despite the availability of a safe and effective hepatitis B vaccine, many individuals remain at
risk of infection. Hepatitis B virus transmission continues in WV due in part to injection drug use
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and substance misuse. Ongoing efforts are needed to identify trends, guide testing and
vaccination programs, and evaluate the effectiveness of those programs.
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